Ranbaxy Laboratories, a member of Daiichi Sankyo Group of Japan, has opened its new manufacturing facility at Casablanca, Morocco, paving the way for a direct business presence in North Africa. With the successful audit of the facility by the Moroccan Health Authorities, Ranbaxy Morocco is now authorized to commence manufacturing of its products at its Casablanca facility. The achievement of this milestone positions Ranbaxy to access a US$ 1 billion pharmaceutical market in Morocco.
Mahendra Bhardwaj, head, Africa region, Ranbaxy, said, “Ranabxy has a significant presence in Africa with its own ground operations in key markets, Morocco is one of the important markets and this manufacturing facility further reinforces our commitment to the people of Morocco and the African continent.”
In addition to servicing the Morocco market, Ranbaxy also plans to extend the supply from this manufacturing unit to other African countries,in the coming years.
The company has a strong presence in Africa. With the addition of Morocco, it now has three manufacturing facilities in Africa; the other two located in Nigeria and South Africa respectively. With five subsidiaries, five representative offices and a strong workforce of nearly a 1,000 people, Ranbaxy's distribution network caters to 44 of the 54 countries in this continent.